Akt抑制剂的临床研究进展

被引：31

作者：

赵艳梅

张建康

蔡兆斌

庄让笑

潘金明

刘寿荣

机构：

[1] 杭州市西溪医院

来源：

中国现代应用药学 | 2017年 / 34卷 / 04期

关键词：

Akt; 临床研究; 哌立福新; MK-2206; GSK2110183; GSK2141795; GDC0068; AZD5363;

D O I：

暂无

中图分类号：

R979.1 [抗肿瘤、抗癌药物];

学科分类号：

100403 [营养与食品卫生学];

摘要：

随着十几个Akt小分子抑制剂先后进入临床研究,Akt已逐渐成为抗肿瘤药物研究的热门靶点。本文主要综述Akt蛋白的结构和功能,同时详细介绍一些已进入临床试验并且极具开发应用前景的小分子Akt抑制剂,如哌立福新、MK-2206、GSK2110183等,并对它们的临床前和临床研究情况进行阐述。

引用

页码：625 / 630

页数：6

共 10 条

[1]

Inhibition of phosphorylated Ser473-Akt from translocating into the nucleus contributes to 2-cell arrest and defective zygotic genome activation in mouse preimplantation embryogenesis [J].

Chen, Junming ;

Lian, Xiuli ;

Du, Juan ;

Xu, Songhua ;

Wei, Jianen ;

Pang, Lili ;

Song, Chanchan ;

He, Lin ;

Wang, Shie .

DEVELOPMENT GROWTH & DIFFERENTIATION, 2016, 58 (03) :280-292

[2]

Phosphorylation of AKT(Ser473) serves as an independent prognostic marker for radiosensitivity in advanced head and neck squamous cell carcinoma [J].

Freudlsperger, Christian ;

Horn, Dominik ;

Weissfuss, Sebastian ;

Weichert, Wilko ;

Weber, Klaus-Josef ;

Saure, Daniel ;

Sharma, Sarika ;

Dyckhoff, Gerhard ;

Grabe, Niels ;

Plinkert, Peter ;

Hoffmann, Juergen ;

Freier, Kolja ;

Hess, Jochen .

INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (12) :2775-2785

[3]

3 Afuresertib (GSK2110183); an oral AKT kinase inhibitor; in combination with carboplatin and paclitaxel in recurrent ovarian cancer.[J].S. Blagden;A. Hamilton;L. Mileshkin;M. Hall;T. Meniawy;S. Wong;S. Anandra;M. Buck;D. McAleer;B.A. Reedy;R.B. Noble;D.A. Smith;S.R. Morris;H. Gabra.European Journal of Cancer.2014,

[4]

A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms [J].

Figg, William D. ;

Monga, Manish ;

Headlee, Donna ;

Shah, Avni ;

Chau, Cindy H. ;

Peer, Cody ;

Messman, Richard ;

Elsayed, Yusri A. ;

Murgo, Anthony J. ;

Melillo, Giovanni ;

Ryan, Qin C. ;

Kalnitskiy, Mikhail ;

Senderowicz, Adrian M. ;

Hollingshead, Melinda ;

Arbuck, Susan G. ;

Sausville, Edward A. .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (05) :955-967

[5]

Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity [J].

Richardson, Paul G. ;

Eng, Cathy ;

Kolesar, Jill ;

Hideshima, Teru ;

Anderson, Kenneth C. .

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2012, 8 (05) :623-633

[6]

Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape [J].

Mattmann, Margrith E. ;

Stoops, Sydney L. ;

Lindsley, Craig W. .

EXPERT OPINION ON THERAPEUTIC PATENTS, 2011, 21 (09) :1309-1338

[7]

Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors.[J].Craig W. Lindsley;Zhijian Zhao;William H. Leister;Ronald G. Robinson;Stanley F. Barnett;Deborah Defeo-Jones;Raymond E. Jones;George D. Hartman;Joel R. Huff;Hans E. Huber;Mark E. Duggan.Bioorganic & Medicinal Chemistry Letters.2004, 3

[8]

High-resolution structure of the pleckstrin homology domain of protein kinase B/Akt bound to phosphatidylinositol (3,4,5)-trisphosphate [J].

Thomas, CC ;

Deak, M ;

Alessi, DR ;

van Aalten, DMF .

CURRENT BIOLOGY, 2002, 12 (14) :1256-1262

[9]

Specificity in pleckstrin homology (PH) domain membrane targeting: a role for a phosphoinositide–protein co-operative mechanism.[J].Tania Maffucci;Marco Falasca.FEBS Letters.2001, 3

[10]

PLECKSTRIN HOMOLOGY DOMAINS: A Common Fold with Diverse Functions.[J].M. J. Rebecchi;S. Scarlata.Annual Review of Biophysics and Biomolecular Structure.1998,

← 1 →